Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors

doi: 10.1007/s00262-023-03464-w

Figure Lengend Snippet: Changes in sPD-1 and sPD-L1 levels after treatment with anti-PD-1 Ab (pembrolizumab or nivolumab) or anti-PD-L1 Ab (atezolizumab). The changes in sPD-1 (A) and sPD-L1 (B) levels after treatment were compared between the subgroups treated with anti-PD-1 Ab (pembrolizumab or nivolumab [Pem/Nivo], N = 139) or anti-PD-L1 Ab (atezolizumab [Atezo], N = 34) using Student’s t-test. Data are shown in box plot format. The bottom and top of the box represent the first and third quartiles, and the band and “X” inside the box correspond to the median and mean, respectively. Whiskers indicate the variability outside the upper and lower quartiles. Outliers are plotted as individual points

Article Snippet: The levels of sPD-1 in plasma were measured by ELISA (Human PD-1 ELISA Kit; RayBio, Norcross, GA) in accordance with the manufacturer’s instructions.

Techniques:

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors

doi: 10.1007/s00262-023-03464-w

Figure Lengend Snippet: Associations between posttreatment sPD-1 and sPD-L1 levels and PFS or OS in NSCLC patients treated with anti-PD-1 Ab monotherapy. (A, B) Patients treated with anti-PD-1 Ab monotherapy were divided into two groups based on their posttreatment sPD-1 levels. Optimal cutoff values for PFS and OS were determined using the Cutoff Finder web application. Kaplan–Meier plots of PFS (A) and OS (B) for the sPD-1low and sPD-1high groups are shown. Differences were statistically analyzed using the log-rank test. (C, D) Patients treated with anti-PD-1 Ab monotherapy were divided into two groups based on posttreatment sPD-L1 levels. Optimal cutoff values for PFS and OS were determined using the Cutoff Finder web application. Kaplan–Meier plots of PFS (C) and OS (D) for the sPD-L1low and sPD-L1high groups are shown. Differences were statistically analyzed using the log-rank test

Article Snippet: The levels of sPD-1 in plasma were measured by ELISA (Human PD-1 ELISA Kit; RayBio, Norcross, GA) in accordance with the manufacturer’s instructions.

Techniques:

Journal: Immunity, Inflammation and Disease

Article Title: Serum soluble PD‐1 plays a role in predicting infection complications in patients with acute pancreatitis

doi: 10.1002/iid3.394

Figure Lengend Snippet: The serum sPD‐1 and sPD‐L1 levels in patients with acute pancreatitis (AP). (A) sPD‐1 and (B) sPD‐L1 were measured in peripheral blood from healthy volunteers (control, n = 30) and patients with AP ( n = 63) on Day 1 (d1), Day 3 (d3), and Day 10 (d10) after onset. * p < .05, ** p < .01

Article Snippet: Serum sPD‐1/sPD‐L1 was quantified using the human sPD‐1/sPD‐L1 enzyme‐linked immunosorbent assay (ELISA) kit (RayBio®).

Techniques:

Journal: Immunity, Inflammation and Disease

Article Title: Serum soluble PD‐1 plays a role in predicting infection complications in patients with acute pancreatitis

doi: 10.1002/iid3.394

Figure Lengend Snippet: The area under the ROC curve (AUC) was used to estimate the accuracy of the predicted model. AUC of serum sPD‐1 level on Day 3: 0.796; AUC of Acute Physiology and Chronic Health Evaluation II score: 0.769; AUC of combined: 0.826

Article Snippet: Serum sPD‐1/sPD‐L1 was quantified using the human sPD‐1/sPD‐L1 enzyme‐linked immunosorbent assay (ELISA) kit (RayBio®).

Techniques: